Larimar Therapeutics Reports Positive Data From Nomlabofusp Phase 2 Study In FA Patients
12/2 13:32
(RTTNews) - Larimar Therapeutics Inc. (LRMR) announced Monday positive top-line data from phase 2 dose exploration study from 25 mg and 50 mg cohorts of Nomlabofusp in patients with Friedreich's Ataxia or FA....